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Introduction {#sec1}
============

A large number of studies support the view that maternal infection, or maternal immune activation (MIA), is a significant contributor to the pathology of autism spectrum disorders (ASD) ([@bib4], [@bib53]). Indeed, a recent study of more than 2 million Swedish women found that having an infection during pregnancy increased the risk of having a child with autism by 37% ([@bib23]). Observations in ASD and models of MIA ([@bib45]) are analogous to those seen in fetal inflammatory response syndrome, where one of the diagnostic markers is an increase in interleukin-6 (IL-6) concentration ([@bib19]). In particular, studies have established that the levels of IL-6 are increased in maternal serum, amniotic fluid, and serum of children subsequently diagnosed with ASD ([@bib3], [@bib15]). Moreover, independent studies have established that children and adults with ASD have higher circulating IL-6 levels compared with controls ([@bib3]). These increases are associated with irritability, impaired communication and sociabilization skills and intelligence. Accordingly, IL-6 is increasingly being used as a biomarker for ASD ([@bib50]).

Infections in pregnant mice and rats, can be mimicked by administering agents that activate the maternal immune system, such as maternal injections of the synthetic double-stranded RNA poly(I:C) (to evoke an anti-viral inflammatory response) or by administering lipopolysaccharide (LPS) (to evoke an anti-bacterial inflammatory response). These immune activators increase circulating levels of cytokines, including IL-6 ([@bib21]) that can cross the placenta and the fetal blood-brain barrier ([@bib1], [@bib52]) to affect the developing brain ([@bib49]). Studies in mice have shown that these immune activators elicit many of the cardinal behavioral features of autism, as well as neuropathological aberrations ([@bib26], [@bib45]). However, it is not clear how these cytokines alter the trajectory of neural development.

At present, the majority of animal models of MIA used to study autism have manipulated the maternal immune system at time points that correspond to the first trimester of human development ([@bib26], [@bib29], [@bib45]). Such studies will affect the primitive neural stem cells (NSCs) and neural stem and progenitors (NSPs) that reside in the neuroepithelium known as the ventricular zone (VZ). However, epidemiological studies on ASD have shown associations between maternal infections in the late second trimester and early third trimester and incidence of ASD ([@bib53]), when proliferative cells in the VZ are declining in number, and the subventricular zone (SVZ) is expanding rapidly to peak in size during early postnatal development. Mice are born precociously, thus the brain of a newborn mouse is equivalent to that of an early third-trimester human infant ([@bib42]). Therefore, to model the effects of maternal inflammation in mice using a more appropriate animal model, we manipulated the levels of IL-6 in the neonatal mouse and asked how this affected the pool of NSCs and progenitors in the SVZ of the forebrain.

Results {#sec2}
=======

Modeling Maternal Infections by Systemically Injecting IL-6 {#sec2.1}
-----------------------------------------------------------

Previous studies have measured 2- to 3-fold increases in the blood plasma IL-6 levels in children with ASD ([@bib3]). Therefore, to determine the dose of IL-6 needed to mimic the increased levels of IL-6 seen in children who will develop ASD, we injected neonatal mice with four doses of IL-6 (40, 75, 150, and 400 ng) versus PBS twice on postnatal day 4 (P4) and once on P5 and then measured plasma levels of IL-6 2 h after the third injection. We used this paradigm to produce sustained increased levels of IL-6 for at least 36 h. Mice that received 40 ng of recombinant mouse IL-6 (rmIL-6) had blood plasma levels of 31 ± 10 pg/mL versus 21 ± 4.3 pg/mL in PBS-injected littermates (1.4-fold increase). Mice that received 75 and 150 ng had blood plasma levels of 43 ± 6.7 pg/mL (2-fold increase) and 58 ± 12 pg/mL (2.7-fold increase) of IL-6, respectively. Finally, mice that received 400 ng IL-6 had 185 ± 32 pg/mL in blood plasma (8.6-fold increase) ([Figure 1](#fig1){ref-type="fig"}A; [Table S1](#mmc1){ref-type="supplementary-material"}). The doses of 75 and 150 ng of IL-6 resulted in blood plasma levels similar to those observed in ASD children. To determine whether these doses were eliciting a systemic response, we measured the body temperature of mice that received 75 and 150 ng of IL-6 1 h after the last injection. The 2- to 3-fold increase in circulating IL-6 caused a small but significant increase in body temperature ([Figure 1](#fig1){ref-type="fig"}B). We decided to use 75 ng of IL-6 for subsequent *in vivo* studies, as it elicited a systemic response inside the range of the blood plasma levels observed in ASD children ([@bib3]).Figure 1Systemic rmIL-6 Administration Increases Blood Plasma Concentration of IL-6 and Body Temperature(A) Blood plasma levels of IL-6 in pg/mL measured by ELISA in groups of at least six mice that received different doses of rmIL-6 or PBS. Error bar indicates SEM from three independent experiments. ^∗∗^p \< 0.01, ^∗∗∗∗^p \< 0.0001 using Student\'s t test. n = 6.(B) Mice body temperature measured 1 h after the last rmIL-6 injection. Numbers over bars represent fold change over PBS group. Error bar indicates SEM from three independent experiments. ^∗^p \< 0.05, ^∗∗∗∗^p \< 0.0001 using Student\'s t test. n = 12 mice.

Elevated Level of IL-6 Increases the Proliferation of PDGF-Responsive Multipotential Progenitors *In Vivo* {#sec2.2}
----------------------------------------------------------------------------------------------------------

We hypothesized that systemically elevating IL-6 would directly affect the NSPs in the developing mouse brain. Using a multi-marker flow panel comprised of CD133/CD140a/NG2/LeX, we have previously established that there are seven subsets of neural progenitors as well as NSCs in the neonatal mouse SVZ ([@bib9]). When isolated by fluorescence-activated cell sorting (FACS) these NSCs and progenitors have different potentialities and growth factor responsiveness *in vitro* ([Table S2](#mmc1){ref-type="supplementary-material"}). To establish how increased levels of IL-6 would affect these NSPs individually *in vivo*, we injected 75 ng of IL-6 twice on P4 mice and once on P5 mice ([Figure 2](#fig2){ref-type="fig"}A) and analyzed changes in NSP proliferation using ethynyl deoxyuridine (EdU) incorporation. Edu (50 mg/kg) was injected twice at intervals of 2 and 4 h before euthanizing the mice for flow cytometry. The gating scheme for the flow cytometry is shown in [Figures 2](#fig2){ref-type="fig"}B and 2C. A significant increase was detected in the proliferation of the platelet-derived growth factor (PDGF) and fibroblast growth factor 2 (FGF-2)-responsive multipotential progenitors (PFMPs) ([Figure 2](#fig2){ref-type="fig"}D; PBS: 8.6% ± 3.45%, IL-6: 22.2% ± 5.32%; p \< 0.05) compared to controls. However, there was no significant change in EdU incorporation into other SVZ cells (NSC, PBS: 14.6% ± 9.09%, IL-6: 15.45% ± 8.94%; multipotential progenitor-1 \[MP1\], PBS: 6.96% ± 3.37%, IL-6: 7.76% ± 3.98%; MP2, PBS: 17.88% ± 10.03%, IL-6: 30.83% ± 8.47%; bipotential neuron astrocyte progenitor \[BNAP\], PBS: 6.64% ± 4.94%, IL-6: 7.99% ± 3.23%; glial-restricted progenitor 3 \[GRP3\], PBS: 4% ± 0.40%, IL-6: 3.19% ± 0.22%; GRP2, PBS: 3.88% ± 0.61%, IL-6: 5.48% ± 0.99%).Figure 2IL-6 Signals to SVZ Cells and Alters the Proliferation of PDGF-Responsive Multipotential Progenitors of SVZ *In Vivo*(A) Schematic of *in vivo* analysis of effects of IL-6 on EdU incorporation into stem cells and progenitors.(B) Gating strategy for flow cytometry.(C) Boxplots of flow cytometry data for PFMPs.(D) Multicolor flow cytometric analysis of pups injected with 75 ng of rmIL-6 on P4 and P5 followed by 50 mg/kg EdU on P5. IL-6 increased EdU incorporation into PFMPs significantly, but not into other SVZ cell types. Data are averaged from three independent experiments. Error bar indicates SEM. ^∗^p \< 0.05 using Student\'s t test. n = 12 male mice. NSC, neural stem cell; PFMP, PDGF/FGF-2-responsive multipotential progenitors; MP, multipotential progenitor; BNAP, bipotential neuronal and astrocytic-associated progenitor; GRP, glial-restricted progenitor.(E) PFMPs were sorted from neurospheres that been treated with 5 ng/mL IL-6 or PBS. Data are presented as fold change from the control group. Error bars represent SEMs from three independent experiments. ^∗^p \< 0.05, ^∗∗^p \< 0.01 using Student\'s t test comparing IL-6-treated samples with untreated controls.

IL-6 Alters Gene Expression of PFMPs *In Vitro* {#sec2.3}
-----------------------------------------------

Whereas others have described PDGF-responsive multipotential progenitors, to date there is very little known about their transcriptome. Therefore, to begin to understand which transcription factors might be involved in the increase in PFMPs, neurospheres were established *in vitro* and PFMPs were sorted as described above. Sorted PFMPs were cultured for 24 h, and then treated with IL-6 (5 ng/mL) and soluble IL-6 receptor (sIL-6R) (5 ng/mL) for 2 h before RNA extraction and qPCR. IL-6 significantly increased the expression of the transcription factor *Fbxo15* (Fc 4.1 ± 2.1, p \< 0.05), while conversely decreasing the expression of *Tlx* (Fc −8.6 ± 0.1, p \< 0.01) and lowered the expression levels of *Dnmt1* below detection levels ([Figure 2](#fig2){ref-type="fig"}E).

SVZ NSPs Express Both GP130 and IL-6R {#sec2.4}
-------------------------------------

As we saw changes in the proliferation of specific NSP subsets in response to IL-6, we asked whether the NSPs express GP130 and IL-6 alpha receptor (IL-6Rα), which comprise the IL-6R complex. Neurospheres were established from P5 mice, propagated for 7 days and then analyzed by western blot. As predicted, these NSPs expressed the IL-6R (68 kDa) and GP130 (130 kDa) receptor, as validated by comparing the NSPs with a macrophage cell line ([Figure 3](#fig3){ref-type="fig"}A). However, neurospheres are a complex mixture of progenitors and stem cells. Therefore, to establish more precisely which cells within the neurospheres express the IL-6R, we performed flow cytometry, combining antibodies to the IL-6R with the four other antibodies used to characterize the NSPs ([Figure 3](#fig3){ref-type="fig"}B). Spleen cells were used as a positive control for the expression of IL-6R. This analysis revealed that BNAP/GRP1, GRP2, MP4, PFMP, and MP2 express IL-6R, whereas receptor expression was below the level of detection for the NSCs, GRP3, and MP1 ([Figure 3](#fig3){ref-type="fig"}C). Altogether, these data demonstrate that most SVZ progenitors can be directly stimulated by the cytokine IL-6.Figure 3SVZ NSPs Express GP130 Receptor and the IL-6Rα and IL-6 Activates pSTAT3 SignalingSVZ NSPs from P5 mice were propagated as neurospheres for 7 days. The macrophage RAW 264.7 cell line (m∅) was used as a positive control.(A) Representative blots for GP130 receptor (130 kDa) and IL-6R⍺ (68 kDa) (see also [Figure S1)](#mmc1){ref-type="supplementary-material"}.(B) SVZ NSP IL-6R⍺ expression was evaluated by flow cytometry. Spleen cells were used as a positive control.(C) Secondary neurospheres were dissociated and analyzed by multi-marker flow cytometry using a panel of antibodies comprised of anti-CD133/LeX/NG2/CD140a/IL-6R. A total of 50,000--100,000 live cells events were analyzed after excluding debris and dead cells using DAPI and gating on positively stained cells based on isotype controls. Data are representative of two independent experiments.(D) Neurospheres from P4 mice propagated for 6 days were treated with 5 ng/mL of rmIL-6, rmIL-6 + 50 ng/mL of sIL-6R, 20 ng/mL of EGF + 10 ng/mL of FGF2, EGF + FGF2 + rmIL-6 + rmIL-6R for 30 min, then samples were analyzed for pSTAT3 and total STAT3.Time course study where samples were analyzed for the phosphorylation of STAT1 (E), STAT3 (F) and MAPK (G) at 15, 30, and 120 min after IL-6 addition. Data representative of three independent experiments. Values represent fold change ± SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.01, as analyzed using ANOVA and Tukey's *post-hoc* test, n = 6.

IL-6 Activates pSTAT-3 in SVZ Neural Precursors in the Absence of sIL-6R Trans-signaling {#sec2.5}
----------------------------------------------------------------------------------------

IL-6 can activate downstream signaling in cells in absence of mIL-6R, via a phenomenon known as trans-signaling where sIL-6R associates with gp130; therefore, cells that do not express the IL-6R may still be affected by IL-6. Once the IL-6 binds to gp130 and to the IL-6R, it activates intracellular tyrosine kinases, such as the Janus kinases (JAKs), which then phosphorylate downstream signaling proteins that include Stat1 and Stat3, the RAS-RAF-MAPK pathway, and the phosphatidylinositol 3-kinase pathway. We investigated these downstream signal pathways upon stimulating SVZ NSPs with IL-6 in the presence or absence of sIL-6R. As shown in [Figure 3](#fig3){ref-type="fig"}D, IL-6 strongly increased levels of pSTAT3 in the NSPs in the absence of trans-signaling. Interestingly, the related cytokine leukemia inhibitory factor (LIF) increased phosphorylation of both STAT3 and STAT1 ([Figures 3](#fig3){ref-type="fig"}E and 3F). A time course analysis revealed that IL-6 activated pSTAT3 significantly within 15 min of addition (p \< 0.05), with further activation up to 30 min, achieving a ∼7-fold increase ([Figure 3](#fig3){ref-type="fig"}F; p \< 0.01) that returned to baseline within 2 h. The phosphorylation of other signaling proteins, such as pSTAT1, pMAPK, pAKT were not significantly affected by IL-6 addition ([Figures 3](#fig3){ref-type="fig"}E and 3G).

IL-6 Increases Tripotentiality in Neurospheres Containing PDGF-Responsive Progenitors, but Not in Neurospheres Enriched for NSCs {#sec2.6}
--------------------------------------------------------------------------------------------------------------------------------

In previous studies, we reported that IL-6 increased the size, number, and self-renewal (beyond four passages) of rat SVZ NSPs compared with controls, which we interpreted as evidence that IL-6 increased the self-renewal of the NSCs ([@bib14]). By contrast, propagating mouse SVZ NSPs at the same cell density and in a medium containing 20 ng/mL epidermal growth factor (EGF), 10 ng/mL FGF-2, and 5 ng/mL IL-6 for 7 days significantly decreased both the number and size of neurospheres formed ([Figures 4](#fig4){ref-type="fig"}A1--A3). This reduction was confirmed by dissociating the secondary neurospheres and analyzing the total number of live cells, which revealed a decrease in the total cell yield from neurospheres treated with IL-6 compared with control (IL-6: 1.4 × 10^6^ versus control: 1.9 × 10^6^). Staining these neurospheres for astrocyte (glial fibrillary acidic protein \[GFAP\]), oligodendrocyte (O4), and neuronal (TUJ1) markers revealed that IL-6 increased the proportion of tripotential neurospheres ([Figure 4](#fig4){ref-type="fig"}A4; 38.9% control versus 51.6% IL-6) to the detriment of bipotential neurospheres ([Figure 4](#fig4){ref-type="fig"}A4; 61.1% control versus 47.3% IL-6). This increase in multipotential cells raised the question whether IL-6 was inducing NSC differentiation toward producing more multipotential progenitors or whether IL-6 was directly affecting the proliferation of multipotential progenitors. To begin answering this question we reduced the cell density to generate clonal neurospheres. In contrast to the previous results, IL-6 treatment decreased neurosphere size but increased the number of the spheres ([Figure 4](#fig4){ref-type="fig"}B1--B3). Under these conditions, there was no increase in the relative number of tripotential neurospheres after IL-6 treatment ([Figure 4](#fig4){ref-type="fig"} B4; 33.3% control versus 27.6% IL-6), but an increase in monopotential neurospheres ([Figure 4](#fig4){ref-type="fig"}B4; 6.7% control versus 27.6% IL-6). These data suggest that the increase in multipotentiality previously observed was not driven by IL-6 directly affecting NSCs. Next, we grew neurospheres under 10 ng/mL FGF-2 and 10 ng/mL PDGFaa, to reduce the number of NSCs in favor of PDGF-responsive progenitors. Under these conditions, IL-6 increased the number of neurospheres, while again reducing sphere size ([Figure 4](#fig4){ref-type="fig"} C1--C3). IL-6 treatment also increased the number of tripotential neurospheres ([Figure 4](#fig4){ref-type="fig"}C4; 40% control versus 53.33% IL-6).Figure 4IL-6 Increases Tripotentiality in Neurospheres Containing PDGF-Responsive Progenitors, but Not in Neurospheres Enriched for NSCsSecondary spheres were propagated in 20 ng/mL EGF + 10 ng/mL FGF-2 ± rmIL-6 (5 ng/mL) at different cell densities.(A1, B1, C1) Representative phase-contrast images of spheres from control and IL-6-treated groups at 7 days *in vitro* (DIV). Scale bars, 400 μm. Neurosphere number and average diameter were quantified at 7 DIV for neurospheres grown from 2.5 × 10^5^ (A2 and A3), 10^4^ (B2 and B3), and 2.5 × 10^5^ cells per mL + PDGFa (C2 and C3). Data are representative of three independent experiments with error bars representing mean ± SEM. At least 120 spheres were measured per group. ^∗∗∗∗^p \< 0.0001, ^∗∗^p \< 0.01, versus control using Student unpaired t test. Neurospheres were differentiated and stained for TuJ1 (neurons) (D1), GFAP (astrocytes) (D2), and O4 (oligodendrocytes) (D3). Scale bars, 50 μm. Thirty spheres from each group were evaluated in each experiment to quantify the number of mono-, bi-, and tripotential spheres (A4, B4, C4). Data are representative of three independent experiments.

IL-6 Increases Proliferation of the PFMP *In Vitro* {#sec2.7}
---------------------------------------------------

To determine how IL-6 was affecting the proliferation of each progenitor and NSCs *in vitro*, we assessed EdU incorporation into the cultured SVZ NSPs using the multi-marker flow panel described above. SVZ NSPs were treated with 5 ng/mL of IL-6 + 5 ng/mL of sIL-6R for 10 h followed by incubation with 10 μM of EdU for 3 h ([Figure 5](#fig5){ref-type="fig"}A). The neurospheres were dissociated and analyzed by flow cytometry. [Figures 5](#fig5){ref-type="fig"}B--5D shows the gating strategy. Live cells were first gated for NG2^+^CD140a^+^, NG2^+^CD140a^−^, NG2^−^CD140a^−^. Next the NG2^+^CD140a^+^ were gated for CD133^+^LEX^+^, CD133^−^LEX^+^, CD133^−^LEX^−^ defined in our previous studies ([@bib9]). We then applied the EdU gating to each population. IL-6 treatment increased the percentage of EdU^+^ PFMPs by 2-fold ([Figure 5](#fig5){ref-type="fig"}E; control: 7.98%; IL-6: 17.8%), whereas it decreased the percentage of GRP3 EdU^+^ cells (control: 27.4%; IL-6: 18.8%), BNAP EdU^+^ cells (control: 19.6%; IL-6: 13.6%), GRP2 EdU^+^ cells (control: 34.7%; IL-6: 21.3%), MP1 EdU^+^ cells (control: 20.4%; IL-6: 13.5%), and NSC EdU^+^ cells (control: 22.1%; IL-6: 12.6%) ([Figures 5](#fig5){ref-type="fig"}F--5J).Figure 5IL-6 Increases PFMP Cell Proliferation and Decreases the Proliferation of NSCs and Other Progenitors *In Vitro*SVZ neurospheres produced from P4 mice were treated with 5 ng/mL rmIL-6. After 10 h, 10 μM EdU was added and 2 h later the cells were analyzed by flow cytometry using a multi-marker panel comprised of anti-CD133/LEX/NG2/CD140a followed by the Click-It reaction for EdU.(A) Schematic of *in vitro* analysis of IL-6 effects on EdU incorporation in SVZ NSPs.(B) Debris and dead cells were excluded using LIVE/DEAD blue.(C and D) (C) After gating on CD140^+^/NG2^+^ cells this subset was separated based on intensity of CD133 and LeX (D).Positively EdU stained cells were gated based on isotype control for PFMP (E), BNAP (F), GRP2 (G), GRP3 (H), MP1 (I) and NSC (J). Data are representative of two independent experiments conducted with triplicate technical replicates.

IL-6 Increases the Proportion of PFMPs *In Vitro*, at the Expense of NSCs and Other Progenitors {#sec2.8}
-----------------------------------------------------------------------------------------------

We used our multi-marker flow panel to establish how IL-6 affected the balance of the specific NSP subsets within the neurospheres. As above, NSPs were propagated as neurospheres in standard growth medium or medium supplemented with 5 ng/mL IL-6 + 5 ng/mL of sIL-6R. The proportion of subtypes was quantified by flow cytometry using: CD133/LeX/NG2/CD140a. A total of 20,000----40,000 live cell events were analyzed after excluding debris and dead cells using DAPI. Positively stained cells were classified by comparison with isotype controls. IL-6 significantly increased the percentage of PFMPs (control: 20.90% ± 0.40%; IL-6: 31.90% ± 0.20%) ([Table 1](#tbl1){ref-type="table"}; p \< 0.001). However, it decreased the proportion of NSCs (control: 0.97% ± 0.011%; IL-6: 0.79% ± 0.027%; p \< 0.05), MP1 (control: 4.65% ± 0.03%; IL-6: 3.33% ± 0.15%; p \< 0.001), MP2s (control: 9.26% ± 0.16%, IL-6: 7.44% ± 0.10%; p \< 0.001), BNAPs (control: 40.23% ± 0.33%; IL-6: 34.6% ± 0.45%; p \< 0.001), GRP2s (control: 6.91% ± 0.15%; IL-6: 5.76% ± 0.030%; p \< 0.05), and GRP3 (control: 5.75% ± 0.12%; IL-6: 6.28% ± 0.08%).Table 1IL-6 Increases the Proportion of PDGF-Responsive Multipotent Progenitors at Expense of NSCs and Other ProgenitorsNSCPFMPMP1MP2BNAP/GRP1GRP3GRP2Control0.97 ± 0.011[a](#tblfn1){ref-type="table-fn"}20.9 0 ± 0.404.65 ± 0.039.26 ± 0.1640.23 ± 0.335.75 ± 0.126.91 ± 0.15IL-60.79 ± 0.027^∗^31.90 ± 0.20^∗∗∗^3.33 ± 0.15^∗∗∗^7.44 ± 0.10^∗∗∗^34.60 ± 0.45^∗∗∗^6.28 ± 0.085.76 ± 0.08^∗^[^2][^3]

IL-6 Decreased the Output of Forebrain Astrocytes from the SVZ {#sec2.9}
--------------------------------------------------------------

After establishing that IL-6 modulated SVZ NSP proliferation, we asked whether increased levels of IL-6 would affect the production of neurons or astrocytes by performing fate mapping using an inducible Nestin-CreERT2/Rosa26-TdTomato reporter mouse. TdTomato expression was induced with 75 mg/kg tamoxifen injection at P1. Reporter mice were injected with 75 ng of IL-6 twice on P4 and once on P5. We evaluated TdTomato-expressing cells at P35 in those regions that would be receiving postnatally differentiating SVZ cells, such as the forebrain and olfactory bulbs, and compared cell numbers between IL-6-injected mice and PBS-injected controls. TdTomato^+^ cells exclusively formed NeuN^+^ neurons in the granule cell layer of the olfactory bulb. However, IL-6 treatment had no affect in the number of those cells ([Figures 6](#fig6){ref-type="fig"}A and 6C). By contrast, IL-6-treated mice had ∼50% fewer postnatally derived astrocytes in the frontal cortex (control: 0.23% ± 11.55%, n = 3; IL-6: 0.1% ± 8.74%, n = 4; p \< 0.001) ([Figures 6](#fig6){ref-type="fig"}D and 6E), as demonstrated by positive staining for S-100b and negative staining for *Olig2* ([Figure 6](#fig6){ref-type="fig"}F).Figure 6IL-6 Changes the Distribution of SVZ-Derived NSPs in Adult Mice Forebrain and Affects Olfaction(A) Fluorescence for TdTomato+ (red) and NeuN+ (green) cells in the glomerular (I), mitral (II), and granule cell (III) layers of the olfactory bulb in IL-6-injected mice and PBS-injected controls. Scale bar, 100 μm. The window shows double magnification.(B) Buried food test. Latency to detect a hidden sugary food pellet (seconds). Error bars represent SEMs from three independent experiments. ^∗^p \< 0.05 using Student\'s t test, comparing IL-6-treated samples with controls.(C) Number of TdTomato+ cells per mm^2^ in the granule cells layer (expanded detail window). Error bars represent SEMs from 3--5 mice per group.(D) Frontal cortex from IL-6-injected and control mice showing TdTomato+ (red) and NeuN+ (green) cells. Scale bar, 500 μm.(E) Number of TdTomato+ cells per mm^2^ in the frontal cortex. Error bars represent SEMs from 3--4 mice per group. ^∗^p \< 0.01 using Student's t test.(F) Confocal image showing co-expression of TdTomato+ and S100b+ cells in astrocytes, and no co-expression of *Olig2*+. Scale bar, 50 μm.

Elevated Neonatal IL-6 Leads to an Olfaction Deficit in the Adult Mice {#sec2.10}
----------------------------------------------------------------------

Although there was no difference in the numbers of new olfactory bulb neurons produced after IL-6 treatment, the possibility existed that the new neurons were inappropriately connected. Therefore, IL-6-treated mice were evaluated using the buried food test at P60 ([@bib55]). This test revealed a significant deficit in olfaction, where the IL-6-injected animals had a 115% increase in latency in finding a sugary-flavored food compared with PBS-injected controls (171.9 versus 80.3; p \< 0.01) ([Figure 6](#fig6){ref-type="fig"}B).

Discussion {#sec3}
==========

Many groups have reported an epidemiologic linkage between maternal infection during pregnancy with neurodevelopmental disorders in the offspring, including developmental delay, cerebral palsy, schizophrenia, and autism ([@bib5], [@bib28], [@bib53]), but how injury- or infection-induced inflammation affects fetal and neonatal brain development is poorly understood. Immune activators, such as LPS and poly(I:C), have been used in the animal models of MIA to highlight the importance of inflammatory cytokines ([@bib43], [@bib45]). Specifically, the relative expression of pro- and anti-inflammatory cytokines in the fetal brain are important for the precise pathological profile emerging in later life. Several studies have clearly indicated that IL-6 is a key mediator of MIA and developmental problems in fetus. For example, one study suggested that a single injection of IL-6 into pregnant mice can mimic the effects of maternal infection on cognitive and behavioral disorders. Furthermore, administering a function-blocking antibody to IL-6 reversed the behavioral deficits induced by MIA in the poly(I:C) model ([@bib45]). The importance of IL-6 is further supported in an LPS model of MIA, where administering the anti-inflammatory drug Pioglitazone abolished the increase in plasma IL-6 levels and ASD-like behaviors ([@bib21]).

In the studies reported here we have begun to test the hypothesis that the proliferation and specification of NSCs and progenitors in the SVZ are altered as a causal component of the development of ASD. To model the increased levels of IL-6 seen with antenatal infections, we established that intraperitoneal injections of 75 ng of IL-6 will increase blood plasma levels of IL-6 by 2-fold. As a consequence, the proliferation of PFMPs increased 2-fold. These multipotential progenitors are likely equivalent to the fetal PDGF-responsive precursors (PRPs) that were shown to be distinct from the NSCs ([@bib56]). They are similar to the PRPs present in the neonatal rat SVZ as described by [@bib31]. This unique and interesting population of neural progenitors has not been well studied. To determine whether IL-6 acts directly on the PFMPs and to establish the underlying mechanisms of action, we demonstrate that the PFMPs (as well as several other SVZ neural progenitors) express IL-6Rα as well as GP130 receptors necessary for downstream IL-6 signaling pathways, and show that IL-6 activates pSTAT3 in these cells. The increased proliferation of PFMPs correlated with enhanced expression of the self-renewal gene *Fbxo15* and with decreased expression of *Tlx* (Nr2e1) and *Dnmt1*. Increased levels of IL-6 not only increased the proportion of PFMPs in the SVZ but also reduced the proportions of NSCs, MP1, BNAP/GRP1, and GRP2.

We postulated that the IL-6-mediated increase in PFMP proliferation could be due to increased expression of transcription factors involved in self-renewal of the neural progenitors. Therefore, we sorted PRPs, stimulated them with IL-6 and analyzed the expression of *Ascl1, Klf4, Id2, Olig2, Fbxo15*, *Tlx*, and *Gsx1*, which have been shown to be important for neural progenitor proliferation. Among those genes we saw an increase in *Fbxo15*, which interestingly, aside from being related to ESC self-renewal and proliferation ([@bib40]), is associated with ASD in patients bearing 18q deletions ([@bib36]). We also found a highly significant decrease in the expression of *Tlx* (Nr2e1). In the hippocampus, *Tlx* promotes proliferation of neural progenitors ([@bib44]) and NSCs ([@bib33], [@bib35]). Consistent with our observation, *Tlx* was previously shown to be repressed by IL-1β, impairing hippocampal neurogenesis and cognition ([@bib39]). Furthermore, *Tlx* null mice show reduced learning and memory ([@bib54]), associated with impaired synaptic plasticity ([@bib13]), hippocampal neuroinflammation ([@bib22]), and decreased expression of synaptic genes ([@bib38]). These synaptic changes correlate with the observation that *Tlx* modulates ASD-relevant behaviors, such as anxiety and fear conditioning ([@bib37], [@bib51]).

A central gene controlling epigenetic regulation of gene transcription and chromatin structure, *Dnmt1*, has been reported to be increased in the brains of mice exposed to diesel exhaust during gestation. Diesel exhaust increases levels of IL-6 in the neonatal brain and produces behavioral outcomes reminiscent of ASD ([@bib10]). In contrast, in our sorted PFMPs, we observed a complete ablation of *Dnmt1* expression. The role of DNMT1 in gliogenesis is complicated. Although DNA demethylation is necessary for STAT3 binding to the Gfap promoter, allowing NPCs to respond to astrocyte-inducing cytokines ([@bib46]), silencing *Dnmt1* in ESCs is not sufficient to induce astrogliogenesis ([@bib47]). However, [@bib17] showed that suppressing *Dnmt1* in neural progenitors was sufficient to drive precocious astroglial differentiation through an increase in STAT signaling ([@bib17]). By contrast, silencing *Dnmt1* in neocortical OPCs suppressed differentiation and induced cell damage ([@bib16]), suggesting that the mechanisms that control methylation are developmental and progenitor cell-type specific.

One suggested explanation for the diverse phenotype observed in ASD is attributed to the disruption of excitatory/inhibitory (E/I) circuit balance during critical periods of development. Neocortical GABAergic parvalbumin-positive inhibitory neurons, which normally drive experience-dependent circuit refinement, are crucial for critical period plasticity. [@bib18] showed that these interneurons were reduced in the neocortex across multiple genetic and non-genetic ASD mouse models ([@bib18]), which would result in decreased numbers of inhibitory synapses. Interestingly, [@bib48] showed that intraventricular injections of IL-6 reduced the formation of inhibitory synapses and affected dendritic spine plasticity in a mouse model that exhibited an ASD-like behavioral phenotype ([@bib48]).

The experimental paradigm used here is quite different from that used in previous MIA studies. For example, [@bib57] provided IL-6 to pregnant mice at the equivalent of the human early first trimester. Thus, their intervention would have affected neuroepithelial cells in the VZ. In contrast, we used neonatal mice to study the effects of increased level of IL-6 on SVZ NSPs at the human fetal equivalent of the beginning of the third trimester as it is this time that best correlates with the development of ASD ([@bib53]). At this stage of development, the SVZ is expanding rapidly, giving rise to distinct sets of late-developing interneurons and glial progenitors that have been shown to be affected in ASD ([@bib18], [@bib25], [@bib27]).

We stably labeled postnatal NSCs to determine whether neonatal inflammation would affect the numbers or types of progeny that they produced in late-developing brain regions. An unexpected result was that olfactory bulb neurogenesis was unaffected in the IL-6-treated mice. In a recently published study, we evaluated SVZ neurogenesis after genetically deleting insulin growth factor II (IGF-II) in adulthood. We reported that this manipulation halved the SVZ NSC numbers, which resulted in an expansion in the progenitor cell pool and with increased numbers of neurons in the olfactory bulb ([@bib55]). More recently we have obtained identical results by deleting the insulin receptor in the NSCs in adulthood (Chidambaram et al., in revision for *Stem Cell Reports*). As the newly added neurons in the olfactory bulb are inhibitory neurons, it was not surprising that the IGF-II and insulin receptor conditional null mice had deficits in olfaction. However, while neonatal IL-6 altered the composition of the SVZ NSP pool, there were no obvious differences in olfactory bulb neuronogenesis, suggesting that the cause of the hyposmia is more subtle.

What our fate mapping studies did reveal was a dramatic reduction in frontal neocortical astrocyte production. Changes in glial cell numbers, or in their state of activation, can subsequently increase or decrease synapse numbers ([@bib2]). A seminal study by [@bib32] showed that transplanting newborn astrocytes into the adult brain could recover cortical synaptic plasticity in an ocular dominance model ([@bib32]). Therefore, a viable hypothesis is that reducing the numbers of astrocytes in the forebrain will upset the E/I synaptic balance producing long-lasting behavioral alterations. Supporting this hypothesis, a study that analyzed a large cohort of ASD patient samples to identify ASD candidate genes found that the largest subset included many genes for synaptic transmission. Further analyses showed that many of those genes were involved in glial cell differentiation and were differentially expressed in the corpus callosum of ASD patients ([@bib25]).

The observation that neonatal IL-6 exposure reduced astrocyte production was somewhat surprising as earlier studies had shown that IL-6 promoted the differentiation of neocortical progenitors into oligodendrocytes and astrocytes ([@bib6], [@bib34]). [@bib58] demonstrated that IL-6 signaling via STAT3 induced NSCs to differentiate into two types of astrocytes. Furthermore, our own earlier studies had shown that IL-6 synergizes with EGF to increase astrocyte proliferation ([@bib24]). Here, we show that IL-6 reduced the abundance of two bipotential glial-restricted progenitors. Therefore, the most parsimonious explanation for the reduced numbers of astrocytes in the frontal lobe is that this was preceded by a loss in the numbers of these bipotential progenitors. At the present time there are no means to fate map these bipotential glial progenitors; however, we are in the process of validating unique markers for these cells based on an RNA sequencing analysis of FACS-purified SVZ progenitors so that these progenitors may be studied in more depth.

In their work, [@bib57] used the neurosphere assay and reported an increase in SVZ neurosphere-initiating cells cultured from adults exposed to IL-6 as fetuses. By contrast, in our experiments, when neurospheres were exposed to IL-6 *in vitro*, we observed a reduction of both sphere number and size. Our results also appear to conflict with those of [@bib14] who showed that IL-6 increased rat SVZ neurosphere number and size. They saw increased production of self-renewing, multipotent progenitors, which was interpreted as an increase in NSCs ([@bib14]). However, neurosphere assays do not allow one to definitely conclude whether a stimulus is increasing the self-renewal and proliferation of NSCs or of multipotential progenitors since the neurosphere assay cannot distinguish between spheres formed by stem cells versus progenitors ([@bib41]). To address that question, we show that clonal neurospheres, which are predominantly formed from NSCs, do not show the same increase in potentiality when treated with IL-6. We also show that IL-6 is directly affecting the progenitors by showing that spheres cultured with FGF-2 and PDGF-A (a condition that is not permissive for NSC self-renewal \[[@bib12]\]), respond to IL-6 with an increase in the number of neuron-generating spheres. This experiment also argues against the conclusion that IL-6 promotes the differentiation of NSCs into tripotential progenitors.

Our data suggest that the multipotential progenitors affected by IL-6 are probably PDGF responsive; however, different populations of multipotential PDGF-responsive progenitors exist in the postnatal SVZ. Therefore, we used a four-color flow cytometry panel, which can distinguish between eight different cell types found in the SVZ. Using this panel, we show that IL-6 increased the proportion of PFMPs, while simultaneously decreasing the proportion of NSCs within neurospheres *in vitro*. This result begins to explain how IL-6 treatment can reduce neurosphere number and size, while increasing multipotentiality. We also showed that IL-6 increased the percentage of EdU^+^ PFMPs by 2-fold compared with the decrease in EdU^+^ NSCs *in vitro* and we confirmed our *in vitro* results *in vivo* using intraperitoneal injections of IL-6, which increased the percentage of EdU^+^ PFMPs. We did not see any significant differences in NSC proliferation, but that can be attributed to long cell-cycle length of the NSCs, which was not captured as we evaluated a single time point. Altogether, these data lead to the conclusion that IL-6 expands the PFMPs at the expense of the NSCs.

It is becoming clear that different progenitor cell types are differentially responsive to IL-6 and that IL-6 can either promote or suppress cell proliferation. [@bib30] showed that the hippocampal neural progenitors expressed IL-6Rs and that an LPS challenge increased hippocampal IL-6R expression. They also showed that IL-6 inhibited hippocampal neurogenesis ([@bib30]). [@bib57] showed IL-6R expression on Sox2^+^ VZ/SVZ precursors. Our flow cytometry data show that PFMP, MP2, GRP2, MP2, and BNAP express IL-6Rα, whereas IL-6Rα is not expressed by NSC, MP1, or GRP3. Those cell types that express membrane-bound IL-6R can be stimulated directly by IL-6, whereas the remainder can be stimulated by IL-6, but only through trans-signaling, which requires the sIL-6Rα.

A number of signaling pathways have been shown to be activated by IL-6 in different CNS cell types, such as JAK and, to a lesser extent, TYK, which, in turn, activate downstream signaling proteins STATs. IL-6 can also activate the RAS-RAF-MAPK and the phosphatidylinositol 3-kinase pathways ([@bib7]). Studies have investigated the activation of pSTAT1 versus pSTAT3 by IL-6 in highly enriched astrocyte compared with microglial cultures ([@bib20]). The astrocytes responded with significant increases in both pSTAT1 and pSTAT3, in contrast IL-6-treated microglia activated pSTAT1 significantly, but not pSTAT3. Therefore, we evaluated signal transduction pathways activated in SVZ NSPs in response to IL-6. We found a significant increase in pSTAT3 signal, but not in pSTAT1, in response to IL-6 and no effect on either pAKT or p44/p42 MAPK. Interestingly, LIF activated both STAT1 and STAT3.

Altogether our studies show that increased blood levels of IL-6 dysregulate the NSPs of the mouse SVZ, increasing PFMP proliferation while simultaneously decreasing the percentage of NSCs as well as two bipotential glial-restricted progenitors. This shift in the composition of the forebrain germinal zone progenitors is accompanied by changes in gliogenesis as well as in olfactory sensitivity. Altogether, these studies provide important new insights into the molecular and cellular underpinnings of neurodevelopmental disorders associated with maternal infections.

Experimental Procedures {#sec4}
=======================

Materials {#sec4.1}
---------

Common laboratory chemicals were purchased from either Sigma or VWR. Cell culture media and supplements were purchased from Invitrogen or Sigma.

Mice {#sec4.2}
----

C57BL/6 mice were generated in-house from mice purchased from Jackson Laboratory (Bar Harbor, ME). C57BL/6 mice were used for neurosphere studies, western blot analyses, and flow cytometry. Swiss Webster mice from time-pregnant females purchased from Charles River laboratories were used for all *in vivo* studies. Only male mice were used for *in vivo* EdU experiments, as ASD is most prevalent in males. All experiments were performed in accordance with protocol 17,064 approved by the IACUC committee of Rutgers University Biomedical Health Sciences.

IL-6 Injections and ELISA {#sec4.3}
-------------------------

P4 Swiss Webster mice were injected twice intraperitoneally with PBS or carrier-free rmIL-6) (R&D Systems, Minneapolis, MN) using a Hamilton syringe separated by 8 h. Trunk blood was collected in 100 USP of Heparin Sodium (Sagent Pharmaceuticals, Schaumburg, IL) 2 h after injection. Samples were centrifuged at 2,000 × *g* for 15 min and then aliquoted and stored at −80°C until analyzed. A mouse IL-6 ELISA Kit (BD OptEIA) was used to analyze the samples.

Neurosphere Experiments {#sec4.4}
-----------------------

Neural progenitors were cultured from SVZs of 4--7-day-old C57BL/6 mice as described previously ([@bib8]). Culture plates for secondary neurospheres were seeded with 2.5 × 10^5^ or 10^4^ cells per mL. Total neurosphere numbers were counted for each experimental replicate under an inverted microscope. Neurosphere diameter was calculated using Zeiss Axiovision and ImageJ software. Cell yield was counted by trypan blue exclusion. Neurospheres were differentiated as described previously and stained for β-tubulin III (TUJ1, 1:300; Covance, Princeton, NJ), GFAP (1:500; Dako, Carpenteria, CA), and O4 (produced in-house). Secondary antibodies included goat anti-mouse IgG2a dylight 488 for TuJ1, goat anti-mouse IgG dylight 549 for GFAP, and goat anti-mouse IgM dylight 647 (Jackson ImmunoResearch, West Grove, PA). Images of stained cells were collected using a Q-imaging Retiga CCD camera (Surrey, BC, Canada) interfaced with iVision scientific imaging software (Scanalytics) on an Olympus AX-70 microscope (Olympus, NJ).

Flow Cytometry Gating {#sec4.5}
---------------------

Flow cytometry was performed as described by [@bib8] using the following antibodies specified in [Tables S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}). Lewis-X (1/20; BD Biosciences), CD133-APC (1/50; eBioscience), CD140a (1/400; BioLegend), and NG2 chondroitin sulfate proteoglycan (1/50; Millipore). EdU experiments were performed as described previously ([@bib11]). Goat anti-rabbit IgG Alexa Fluor 700 (1/100; Invitrogen) was used for NG2. DAPI was used for dead cell exclusion. IL-6Rα was analyzed using the flow panel described above with the addition of an antibody against IL-6Rα (1/20, R&D Systems). All sample data were collected on a BD LSR II (BD Biosciences) and analyzed using FlowJo.

Quantitative Real-Time PCR Analysis {#sec4.6}
-----------------------------------

SVZ NSPs were propagated as neurospheres in medium supplemented with 20 ng/mL EGF and 10 ng/mL FGF-2. Neurospheres were dissociated, propagated for 4 days, and PFMPs were sorted using FACS. Sorted cells were cultured in the absence or presence of rmIL-6 (5 ng/mL) + slIL-6R (5 ng/mL) for 2 h. RNA was isolated using NucleoSpin RNA Plus Kit (Macherey-Nagel), amplified and cDNA generated using iScript cDNA synthesis kit (Bio-Rad). qPCR was performed using 100 ng of cDNA and validated QuantiTect SYBR Green primers (QIAGEN) on an CFX 96 real-time PCR system (Bio-Rad). 18S RNA and actb were used as normalization controls. Relative quantification was evaluated by the ΔΔ Ct method.

Western Blots {#sec4.7}
-------------

Exponentially growing cultures of neural progenitors were treated ± IL-6/sIL-6R for 30 min and harvested at the indicated time points. The cells were washed with ice-cold PBS, then placed into lysis buffer (50 mM Tris-HCl \[pH 7.6\], 50 mM NaCl, 0.1% sodium dodecyl sulfate, 1% Triton X-100) and protease inhibitors. The lysates were sonicated, then clarified by centrifugation at 10,000 × *g* at 4°C for 15 min. Aliquots of 30--50 μg of protein of lysate were fractionated on 4%--12% SDS-polyacrylamide gels and transferred to nitrocellulose membranes. The blots were developed using antibodies to the phosphorylated and non-phosphorylated forms of the following signal transduction proteins: pSTAT3, pSTAT1, MAPK, and AKT (all from Cell Signaling Technology, Danvers, MA). Independent experiments were repeated at least three times. For IL-6R expression, RAW 264.7 cell lysate was used as a positive control. Blots were developed for IL-6Rα and for GP130 (antibodies from R&D Systems) followed by chemiluminescent detection using Western Lightning Plus-ECL (PerkinElmer, Waltham, MA) and ChemiDoc Touch imaging system (Bio-Rad).

Statistical Analyses {#sec4.8}
--------------------

For all datasets, statistical analyses were performed using Student\'s unpaired t test and ANOVA followed by Tukey\'s *post-hoc* multiple comparison test. A p \< 0.05 was considered significant. In figures, asterisks denote statistical significance marked by ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. GraphPad Prism (version 5.01) was used for all analyses. Sample sizes (n) are indicated in the figure legends.
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